Grilled by journalists and analysts during Roche's quarterly sales update about the purchase of Flatiron Health Inc., the Swiss group's CEO and pharma chief explained in detail how acquiring the oncology-focused electronic health record company will give valuable access to real-world evidence (RWE) data that Roche aims to use to better design clinical trials and outcomes, improve chances for drug reimbursement, and thus reinforce its place as a leader in oncology therapeutics.
Answering questions on April 26 while outlining its first-quarter sales performance – which saw revenue from new drugs offset erosion...